Product Abuse-deterrent property FDA approval date Sponsor Company
Oxycontin® (oxycodone CR Tab) • Mechanical resistance
• Gelling in solvents
April 2010 (original formulation: December 1995) Purdue Pharma
Nucynta® ER (tapentadol ER tab) • Mechanical resistance ¬†August 2011 Johnson & Johnson/ Janssen Pharmaceuticals
Exaglo® (hydromorphone ER tab) • OROS technology, hard outer shell
• Gelling in solvents
March 2010 Mallinckrodt
Opana® ER (oxymorphone ER tab) • Crush resistant
• “Intac technology” byGrunenthal
December 2011 Endo Pharmaceuticals
Oxecta® (oxycodone tab) • Gels in liquid
• Nasal irritant
• “Aversion technology” byAcura Pharmaceuticals
June 2011 Pfizer Inc. (formerly King Pharmaceuticals) 
Embeda™ (morphine/naltrexone ER cap) • Mixed agonist/antagonist
• Sequestered antagonist
August 2009 (Voluntarily Recalled Mar. 2011) Pfizer Inc. (formerly King Pharmaceuticals)
CR, controlled release; ER, extended release; only product with approved abuse-deterrent labeling
Table 1: FDA approved products with properties expected to reduce abuse.